CD274 and non-small cell lung carcinoma: In contrast, the KEYNOTE-042 phase 3 randomized trial demonstrated that first-line pembrolizumab monotherapy results in superior efficacy and safety versus chemotherapy in patients with advanced NSCLC and PDL1 TPS ≥1%.